Protein C
| |
| Blood Coagulation (Thrombin) Pathway, and Protein C Pathway. John H. Griffin PhD., TSRI | |
| protein C
| |
| Identifiers | |
| Symbol | PROC |
| Entrez | 5624 |
| HUGO | 9451 |
| OMIM | 176860 |
| RefSeq | NM_000312 |
| UniProt | P04070 |
| Other data | |
| Locus | Chr. 2 q13-q21 |
|
WikiDoc Resources for Protein C | |
|
Articles | |
|---|---|
|
Most recent articles on Protein C | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Protein C at Clinical Trials.gov Clinical Trials on Protein C at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Protein C
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Protein C Discussion groups on Protein C Directions to Hospitals Treating Protein C Risk calculators and risk factors for Protein C
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Protein C | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Protein C is a major physiological anticoagulant. It is a vitamin K-dependent serine protease enzyme (EC 3.4.21.69) that is activated by thrombin into activated protein C (APC). The activated form (with protein S as a cofactor) degrades Factor Va and Factor VIIIa. It should not be confused with C peptide or c-reactive protein or protein kinase C.
The protein C pathway’s key enzyme, activated protein C, provides physiologic antithrombotic activity and exhibits both anti-inflammatory and anti-apoptotic activities. Its actions are related to development of thrombosis and ischemic stroke. The protein C pathway of the coagulation of the blood involves the influences of lipids and lipoproteins and the study of the strong epidemiologic association between hyperlipidemia and hypercoagulability.[1]
- See: detailed diagram of Blood Coagulation (Thrombin) and Protein C Pathways
Role in disease
Protein C deficiency is a rare genetic disorder that predisposes to venous thrombosis and habitual abortion. If homozygous, this presents with a form of disseminated intravascular coagulation in newborns termed purpura fulminans; it is treated by replacing the defective protein C.
Activated protein C resistance is the inability of protein C to cleave factors V and/or VIII. This may be hereditary or acquired. The best known and most common hereditary form is Factor V Leiden. Acquired forms occur in the presence of elevated Factor VIII concentrations.
Warfarin necrosis is acquired protein C deficiency due to treatment with the vitamin K inhibitor anticoagulant warfarin. In initial stages of action, inhibition of protein C may be stronger than inhibition of the vitamin K-dependent coagulation factors (II, VII, IX and X), leading to paradoxical activation of coagulation and necrosis of skin areas.
HDL and the effects of activated protein C (APC) on cells is very important.[2]
Pharmacology
Drotrecogin alpha (activated) is recombinant activated protein C from Ely Lilly Co, USA. It is used in the treatment of severe sepsis, septic shock and disseminated intravascular coagulation.
Genetics
The PROC gene is located on the second chromosome (2q13-q14).
See also
References
- ↑ Thrombosis, Blood Coagulation and the Antithrombotic Protein C Pathway - John H. Griffin, TSRI
- ↑ Blood review by Mosnier, Zlokovic and Griffin 2006 ePub
- ↑ Activated protein C resistance
External links
- Relative antithrombotic and antihemostatic effects of protein C activator versus low molecular weight heparin in primates, Gruber A, Marzec UM, Bush L, Di Cera E, Fernandez JA, Berny MA, Tucker EI, McCarty OJ, Griffin JH, Hanson SR., Blood (2007)
- The cytoprotective protein C pathway, Mosnier LO, Zlokovic BV, Griffin JH., Blood (2006)
- The Protein C Pathway- John H. Griffin, TSRI, La Jolla, California
- Diagram of The Blood Coagulation Pathway and Protein C Pathway
Proteins: coagulation | |
|---|---|
| Coagulation factors | intrinsic pathway (FXII, FXI, FIX, FVIII) - extrinsic pathway (Tissue factor, FVII) - common pathway (FX, FV, (Pro)thrombin / FII, Fibrin / FI, FXIII) - HMWK - vWF - Kallikrein |
| Inhibitors | Antithrombin - Protein C - Protein S - Protein Z - ZPI - TFPI |
| Fibrinolysis | Plasmin - tPA/urokinase - PAI-1/2 - α2-AP - α2-macroglobulin - TAFI |
WikiDoc Research Resources for Protein C | |
|---|---|
| Articles on Protein C | Most recent articles on Protein C • Most cited articles on Protein C • Review articles on Protein C • Articles on Protein C in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Protein C | Powerpoint slides on Protein C • Images of Protein C • Photos of Protein C • Podcasts & MP3s on Protein C • Videos on Protein C |
| Evidence Based Medicine Regarding Protein C | AND (Cochrane Database Syst Rev[http://worldselectshop.com/?id=9361 Cochrane Collaboration on Protein C • Bandolier on Protein C • TRIP on Protein C |
| Cost Effectiveness of Protein C | AND (Cost effectiveness) |
| group5 = Clinical Trials Involving Protein C | list5 = Ongoing Trials on Protein C at Clinical Trials.gov • Trial results on Protein C • Clinical Trials on Protein C at Google
| group6 = Guidelines / Policies / Government Resources (FDA/CDC) Regarding Protein C
| list6 = US National Guidelines Clearinghouse on Protein C • NICE Guidance on Protein C • NHS PRODIGY Guidance • FDA on Protein C • CDC on Protein C
| group7 = Textbook Information on Protein C
| list7 = Books and Textbook Information on Protein C
| group8 = Pharmacology Resources on Protein C
| list8 =
AND (Dose)}} Dosing of Protein C • AND (drug interactions)}} Drug interactions with Protein C • AND (side effects)}} Side effects of Protein C • AND (Allergy)}} Allergic reactions to Protein C • AND (overdose)}} Overdose information on Protein C • AND (carcinogenicity)}} Carcinogenicity information on Protein C • AND (pregnancy)}} Protein C in pregnancy • AND (pharmacokinetics)}} Pharmacokinetics of Protein C •
| group9 = Genetics, Pharmacogenomics, and Proteinomics of Protein C
| list9 =
AND (pharmacogenomics)}} Genetics of Protein C • AND (pharmacogenomics)}} Pharmacogenomics of Protein C • AND (proteomics)}} Proteomics of Protein C
| group10 = Newstories on Protein C
| list10 = Protein C in the news • Be alerted to news on Protein C • News trends on Protein C</small>
| group11 = Commentary on Protein C
| list11 =
Blogs on Protein C
| group12 = Patient Resources on Protein C | list12 = Patient resources on Protein C • Discussion groups on Protein C • Patient Handouts on Protein C • Directions to Hospitals Treating Protein C • Risk calculators and risk factors for Protein C
| group13 = Healthcare Provider Resources on Protein C
| list13 =
Symptoms of Protein C • Causes & Risk Factors for Protein C • Diagnostic studies for Protein C • Treatment of Protein C
| group14 = Continuing Medical Education (CME) Programs on Protein C | list14 = CME Programs on Protein C
| group15 = International Resources on Protein C | list15 = Protein C en Espanol • Protein C en Francais
| group16 = Business Resources on Protein C | list16 = Protein C in the Marketplace • Patents on Protein C
| group17 = Informatics Resources on Protein C | list17 = List of terms related to Protein C
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
